TY - JOUR AU - Bumrungsawat, Maythaporn AU - Ratanasuwan, Winai AU - Tipayamongkholgul, Mathuros AU - Larpparisuth, Nuttasith PY - 2021/01/12 Y2 - 2024/03/29 TI - Risk factors of receiving tenofovir related to renal Insufficiency in patients JF - Journal of Preventive Medicine Association of Thailand JA - JPMAT VL - 10 IS - 3 SE - Original Article DO - UR - https://he01.tci-thaijo.org/index.php/JPMAT/article/view/247072 SP - 366-382 AB - <p>&nbsp; &nbsp; &nbsp;Tenofovir was an antiviral drug to use for the treatment of HIV infection with its side effects on the kidneys of HIV-infected patients. This study aimed to study other relevant risk factors for the incidence of the renal insufficiency in HIV patients were aged ≥ 18 years who had registered and ever received tenofovir-based regimen at Infectious Diseases and Immunodeficiency Clinic of Siriraj hospital and Medical Outpatient Department of Bamrasnaradura Infectious Diseases Institute between 1<sup>st</sup> January 2005 and 30<sup>th</sup> June 2011 with a retrospective cohort study to perform at least 72 months. The total subjects of this study included 241 subjects. The follow-up time was 13.71 100PYs; 41 showed renal insufficiency and 2.99 per 100PYs of incidence rate. After multivariate adjustment for other factors in TDF group by Cox proportional hazards models, HIV patients who had received other ARV drugs before follow-up had a 3.126 fold greater risk for renal insufficiency than those who had not received other ARV drugs before follow-up (Hazard ratio = 3.126, 95% CI for HR 1.380-7.083, P-value = 0.006).</p><p>&nbsp;&nbsp;&nbsp;&nbsp; The results of this study supported other studies in related fields which found that to receive ARV drugs prior to enrollment for this research was associated with the incidence of renal insufficiency. Moreover, the most rapid period of renal insufficiency occurrence was approximately 5.8 months which was considered to be relatively fast.</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Therefore, use of ARV drugs should be closely monitored for renal function and other factors gained from the statistical analysis, but no findings associated with this study should not be overlooked in the clinical treatment. The results of this study will be beneficial to HIV-infected patients as well as to hospitals to utilize them for planning the public health policy to reduce the complications causing the incidence of renal toxicity by ARV drugs usage.</p> ER -